DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.

GGG's fourth-quarter 2024 sales decline 3% year over year due to lower demand in the Industrial segment.

PKG's Q4 results reflect the impacts of higher volume and price/mix in both segments.

BRO's fourth-quarter results reflect improved organic revenues, driven by higher commission and fees and investment income and expanded EBITDAC...

NAVI's Q4 earnings benefit from an increase in other income and a decline in expenses. However, lower NII remains a concern.

HES' Q4 earnings gain from increased oil-equivalent production and lower costs, though partially weighed down by weaker realized crude and natural gas...

ARE's Q4 results reflect a year-over-year rise in revenues, backed by decent leasing activity and higher rental rates despite higher interest...

PG's Q2 results reflect robust organic sales rise, core EPS growth and strong cash returns to shareholders. It remains on track to reach its fiscal...

Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in...

HZO's Q1 results reflect a y/y decline in comps, but its margin profile improves on acquisitions and organic growth, boosting resilience.